Dalibor Valík

1.7k total citations
73 papers, 1.1k citations indexed

About

Dalibor Valík is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Dalibor Valík has authored 73 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 20 papers in Molecular Biology and 17 papers in Immunology. Recurrent topics in Dalibor Valík's work include Childhood Cancer Survivors' Quality of Life (7 papers), Cancer Immunotherapy and Biomarkers (6 papers) and Immunotherapy and Immune Responses (6 papers). Dalibor Valík is often cited by papers focused on Childhood Cancer Survivors' Quality of Life (7 papers), Cancer Immunotherapy and Biomarkers (6 papers) and Immunotherapy and Immune Responses (6 papers). Dalibor Valík collaborates with scholars based in Czechia, United States and Germany. Dalibor Valík's co-authors include Jaroslav Štěrba, Bořivoj Vojtěšek, Lenka Zdražilová Dubská, Regina Demlová, Michael A. Sheard, Viera Bajčiová, Rudolf Nenutil, Rostislav Vyzula, Ladislav Dušek and Zdeněk Pavelka and has published in prestigious journals such as SHILAP Revista de lepidopterología, Scientific Reports and International Journal of Molecular Sciences.

In The Last Decade

Dalibor Valík

68 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Dalibor Valík Czechia 18 474 300 212 155 119 73 1.1k
Jennifer H. Foster United States 15 429 0.9× 262 0.9× 282 1.3× 81 0.5× 82 0.7× 63 1.1k
Gudrun Pohl Austria 19 661 1.4× 579 1.9× 237 1.1× 122 0.8× 95 0.8× 35 1.4k
Jeffrey Skolnik United States 17 554 1.2× 518 1.7× 129 0.6× 95 0.6× 146 1.2× 32 1.2k
Hie‐Won Hann United States 24 648 1.4× 223 0.7× 314 1.5× 132 0.9× 190 1.6× 70 2.1k
Alice Chin United States 14 426 0.9× 223 0.7× 128 0.6× 362 2.3× 69 0.6× 24 1.1k
Peter O’Gorman Ireland 23 654 1.4× 571 1.9× 122 0.6× 225 1.5× 131 1.1× 72 1.8k
Benjamin D. Hedley Canada 16 464 1.0× 544 1.8× 228 1.1× 85 0.5× 93 0.8× 40 1.1k
Antje Lebrecht Germany 23 407 0.9× 610 2.0× 305 1.4× 215 1.4× 42 0.4× 58 1.4k
Edgar Jost Germany 23 1.0k 2.1× 392 1.3× 183 0.9× 314 2.0× 318 2.7× 100 1.8k
Claudio Cerchione Italy 20 574 1.2× 585 1.9× 121 0.6× 195 1.3× 115 1.0× 123 1.3k

Countries citing papers authored by Dalibor Valík

Since Specialization
Citations

This map shows the geographic impact of Dalibor Valík's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dalibor Valík with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dalibor Valík more than expected).

Fields of papers citing papers by Dalibor Valík

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dalibor Valík. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dalibor Valík. The network helps show where Dalibor Valík may publish in the future.

Co-authorship network of co-authors of Dalibor Valík

This figure shows the co-authorship network connecting the top 25 collaborators of Dalibor Valík. A scholar is included among the top collaborators of Dalibor Valík based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dalibor Valík. Dalibor Valík is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Valík, Dalibor, et al.. (2023). Revisiting treatment-related cardiotoxicity in patients with malignant lymphoma—a review and prospects for the future. Frontiers in Cardiovascular Medicine. 10. 1243531–1243531. 2 indexed citations
2.
Selingerová, Iveta, et al.. (2022). Sunitinib-Induced Elevation of Mean Corpuscular Volume (MCV)—Exploring Its Possible Clinical Relevance in Cancer Patients. Current Oncology. 29(6). 4138–4147. 2 indexed citations
3.
Pokorná, Petra, Giannoula Klement, Veronika Kanderová, et al.. (2022). Minimal Residual Disease–Guided Intermittent Dosing in Patients With Cancer: Successful Treatment of Chemoresistant Anaplastic Large Cell Lymphoma Using Intermittent Lorlatinib Dosing. JCO Precision Oncology. 6(6). e2100525–e2100525. 2 indexed citations
4.
Dubská, Lenka Zdražilová, et al.. (2021). Strict Adherence to Anti-Epidemic Measures Prevents ICU Staff from SARS-Cov2 Infection. Biomedical & Pharmacology Journal. 14(4). 1881–1885. 1 indexed citations
5.
Holub, Petr, Łukasz Kozera, David van Enckevort, et al.. (2020). BBMRI-ERIC’s contributions to research and knowledge exchange on COVID-19. European Journal of Human Genetics. 28(6). 728–731. 16 indexed citations
6.
Selingerová, Iveta, Zdeněk Řehák, Dalibor Valík, et al.. (2019). Assessment of Immune Response Following Dendritic Cell-Based Immunotherapy in Pediatric Patients With Relapsing Sarcoma. Frontiers in Oncology. 9. 1169–1169. 13 indexed citations
7.
Dubská, Lenka Zdražilová, Peter Múdrý, Pavel Mazánek, et al.. (2017). Immunomonitoring of patients treated with personalized dendritic cell-based vaccine. Annals of Oncology. 28. xi17–xi17. 2 indexed citations
8.
Dubská, Lenka Zdražilová, Eva Hlaváčková, Eva Matoulková, et al.. (2016). TKI pazopanib impaires immunostimulatory properties of monocytes: Implication for monocyte-derived DC-based anti-cancer vaccine preparation. Annals of Oncology. 27. viii6–viii6. 1 indexed citations
9.
Obermannová, Radka, Ladislav Dušek, Jiří Jarkovský, et al.. (2015). Time-course pattern of blood 25-hydroxycholecalciferol is a significant predictor of survival outcome in metastatic colorectal cancer: a clinical practice-based study. Neoplasma. 62(6). 958–965. 7 indexed citations
10.
Bortlíček, Zbyněk, Jana Halámková, Igor Kišš, et al.. (2015). Efficacy of bevacizumab and chemotherapy in the first-line treatment of metastatic colorectal cancer: broadening KRAS-focused clinical view. BMC Gastroenterology. 15(1). 37–37. 19 indexed citations
11.
Vašků, Julie Bienertová, Lenka Zdražilová Dubská, Radka Obermannová, et al.. (2013). Vitamin D – jeho fyziologie, patofyziologie a význam vetiopatogenezi nádorových onemocnění. 152(1).
12.
Holub, Petr, et al.. (2012). The biobanking research infrastructure BBMRI_CZ: a critical tool to enhance translational cancer research.. PubMed. 25 Suppl 2. 2S78–81. 4 indexed citations
13.
Štěrba, Jaroslav, Zdeněk Pavelka, Nicolás André, et al.. (2009). Second complete remission of relapsed medulloblastoma induced by metronomic chemotherapy. Pediatric Blood & Cancer. 54(4). 616–617. 17 indexed citations
14.
Ošlejšková, Hana, Jaroslav Štěrba, Zdeněk Pavelka, et al.. (2008). Malignant Intracranial Germinoma in Smith-Lemli-Opitz Syndrome: Cholesterol Homeostasis Possibly Connecting Morphogenesis and Cancer Development. Journal of Pediatric Hematology/Oncology. 30(9). 689–691. 6 indexed citations
15.
Knoflíčková, Dana, Lenka Hernychová, Pavel Bouchal, et al.. (2007). Identifikace potenciálních biomarkerů karcinomů prsu metodouSELDI-TOF MS. Klinicka onkologie. 20(6).
16.
Valík, Dalibor, Martin Radina, Jaroslav Štěrba, & Bořivoj Vojtěšek. (2006). Homocysteine: a promising biomarker of folate antagonist chemotherapy. 14(2). 75–83. 1 indexed citations
17.
18.
Valík, Dalibor, et al.. (2003). What We Currently Know about the Structure and Function of the p53 Homologue - p73 Protein: Facts, Hypotheses and Expectations. Folia Biologica. 49(1). 1–8. 1 indexed citations
19.
Sheard, Michael A., et al.. (2002). Release of cytokeratin‐18 and ‐19 fragments (TPS and CYFRA 21‐1) into the extracellular space during apoptosis. Journal of Cellular Biochemistry. 85(4). 670–677. 81 indexed citations
20.
Macháčková, Eva, Jiřı́ Damborský, Dalibor Valík, & Lenka Foretová. (2001). Novel germline BRCA1 and BRCA2 mutations in breast and breast/ovarian cancer families from the Czech Republic. Human Mutation. 18(6). 545–545. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jennifer H. Foster Breakdown of academic impact, for papers by Gudrun Pohl Breakdown of academic impact, for papers by Jeffrey Skolnik Breakdown of academic impact, for papers by Hie‐Won Hann Breakdown of academic impact, for papers by Alice Chin Breakdown of academic impact, for papers by Peter O’Gorman Breakdown of academic impact, for papers by Benjamin D. Hedley Breakdown of academic impact, for papers by Antje Lebrecht Breakdown of academic impact, for papers by Edgar Jost Breakdown of academic impact, for papers by Claudio Cerchione
Rankless by CCL
2026